

South West Critical Care Network Core Principles for Infection Prevention & Control hospital transfers and repatriations.

Agreement. This guidance has been approved by Infection Prevention and Control (IP&C) Teams within the South West and the South West Critical Care Network (SWCCN).

Principles. Critical care patients may need to be transferred between organisations, within the SWCCN for purposes of escalation, repatriation, and mutual aid. Unnecessary delays to patient transfer, due to the requirement for a single room and/or use of single rooms within receiving hospital /unit may delay the care of the transferred patient, as well as other patients across the South West. Clinical risk assessment should consider the risk of delayed transfer, as well as the risk of possible infection. Referrals or repatriations should not be refused because of colonisation/infection. Appropriate IPC precautions, placement and prioritisation should be in place to facilitate safe patient transfer.

IPC precautions should follow the specific guidance as outlined in the [National Infection Prevention and Control Manual](#) and the A-Z of pathogens, [NHS-England-IPC-A-to-Z-pathogen-resource-draft-4.xlsx \(live.com\)](#). The hierarchy of controls should be used to formulate a risk assessment, elimination, substitution, engineering controls, administrative controls, and personal protective equipment (PPE) respectively. **(Link to HOC to be added when updated)**

Pre-Transfer Communication:

A detailed, effective handover between referring and receiving organisations is key to safe patient care. If there is a particular IPC element to the transfer, e.g., the patient is infected or colonised with a multidrug resistant organism (MDRO) and/or transmissible organism, then IPC teams may be required to be involved from the referring and receiving organisation.

If the patient is in an area where there is a suspicion or confirmed outbreak/cluster of an organism, which requires IPC precautions, the IPC teams must be involved from both the referring and receiving organisations.

If there is an IPC element that may delay transfer, this must be discussed with the IPC teams.

Screening swab results.

Screening swabs should be taken as per national guidance and local policy. Receiving organisations should accept results as documentary evidence. All results, positive or

negative, should be provided by the referring organisation. There may be exceptional situations when additional screening may be requested by the receiving IPC team. An example of this may be in an outbreak situation. The table below sets out the screening requirements as stated in the national guidance.

To inform a risk assessment, the following screens should be completed as per national guidance and local policy. If the screens have not been completed as described in the table below, then isolating a patient in the receiving organisation may be necessary until the tests results have been received and reviewed.

Organism	Screening criteria	Swabs Required
<p>MRSA</p> <p>Implementation of modified admission MRSA screening guidance for NHS (2014)</p> <p>MRSA screening guidance(publishing.service.gov.uk)</p>	<p>All patients admitted to critical care (classified as a high-risk units/location). The frequency of (repeat) screening should be determined locally and made explicit in local guidance – the majority of SWCCN hospitals require swabs on admission.</p>	<p>Nose, groin/perineum and ‘other’ sites where appropriate (e.g. wounds, indwelling devices, throat, etc).</p>
<p>CPE</p> <p>Framework of actions to contain carbapenemase-producing Enterobacterales (2022).</p> <p>Actions to contain carbapenemase-producing Enterobacterales (publishing.service.gov.uk)</p>	<p>Current guidance advises that anyone who has been an inpatient within the past 12 months requires CPE screening, therefore anyone transferred between critical care units will require a CPE swab.</p> <p>Specifically: All patients in the last 12 months, if they have: Been previously identified as CPE positive. Been an inpatient in any hospital, in the UK or abroad. Had multiple hospital treatments, for example are dialysis dependent. Had known epidemiological link to a known carrier of CPE.</p>	<p>A rectal swab, making sure faecal material and/or discoloration is visible on the swab (a stool specimen if a rectal swab is not feasible or acceptable) a wound swab and or a urine sample (if catheterised)</p>
<p>Covid 19:</p>	<p>Symptomatic adults and children</p>	<p>PCR and LFD at local discretion</p>

<p>Full guidance available. COVID-19: testing from 1 April 2024 - GOV.UK (www.gov.uk)</p>	<p>admitted for care or developing symptoms within hospitals where having COVID-19 will change clinical management, for example to inform treatment</p>	
<p><i>C. auris:</i> Guidance for the laboratory investigation, management and infection prevention and control for cases of <i>Candida auris</i> (2017).</p> <p>C. auris main guidance, v.2.0 (includes revisions made to the text for clarity) (publishing.service.gov.uk)</p> <p><u>New guidance to be published. Date to be confirmed.</u></p>	<p>All Patients coming from other affected hospitals/units in the UK and abroad.</p>	<p>Groin and axilla (the most persistently positive in Trusts that have conducted screening).</p>

Use of single rooms.

Routine isolation of patients in single rooms when transferred from one organisation to another may not be required if:

- the above screens are negative
- screens have been taken within an appropriate timescale for transfer (according to receiving organisations local policy, e.g., 72 hours)
- the patient is not known to be previously or currently infected or colonised with an MDRO

If this is not the case, the transfer should not be delayed, and the patient should be isolated on arrival until a risk assessment has occurred. If no isolation room is available, patients must be individually assessed for infection risk, if possible, before transfer or promptly on arrival. This assessment should influence placement decisions in accordance with clinical/care need(s). (National Infection Prevention and Control Manual)

Where test results indicate the need for continued IPC precautions, the receiving IPC team will advise on the requirements for isolation, cohort nursing or hierarchies of control. Where the IPC results described above have been appropriately obtained and a detailed handover has occurred to the referring organisation, re-testing to facilitate release from a single room in a receiving hospital may not be required.

Patients with known immunodeficiency may require single room placement for protective isolation.

Possible Risk Assessment Considerations:

Acute trusts will need to make their own risk assessment based on regional prevalence, patient mix, and linkages with other care providers. (UKHSA 2022). Other considerations include:

- Whether the patient previously or currently infected or colonised with an MDRO or significant organism (for example *Candida auris*, *C. difficile*, viral respiratory illness such as Covid-19)
- Whether the patient is a known 'contact' of any of the following: MRSA, CPE, *Candida auris*
- There have been occurrences or outbreaks/periods of increased incidence of MDRO or other significant organisms in the past. e.g. 3 months, (CPE, GRE, *C. difficile*, *Candida auris*).

Please report any delays in transfers related to IPC issues to:

Southwest Critical Care Network swccn@uhbw.nhs.uk or David.cain6@nhs.net

David Cain – Peninsula sub region Lead.
Southwest Critical Care ODN

Graham Brant – Network Manager & Lead Nurse
Southwest Critical Care ODN

Andy Georgiou - Director
Southwest Critical Care ODN

Jo Coles
Infection Prevention & Control, Clinical Advisor
NHS England Southwest